Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
BRIA-ABC trial: what clinicians have said so far
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
- NCT06072612 ↗
- Recruiting
- BriaCell Therapeutics Corporation
- Focused size, estimated: 1–150 verified statements once built
Discussed at: AACR Annual Meeting 2026, 2026 ASCO Annual Meeting
We haven't built an HCP commentary report on BRIA-ABC yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on BRIA-ABC so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 4 posts on X, typically up to 18 once built |
The trial
ClinicalTrials.gov- Official title
- Randomized, Open-Label Study of the Bria-IMT Regimen and Check Point Inhibitor vs Physicians' Choice in Advanced Metastatic Breast Cancer.
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Breast Cancer; Metastatic Breast Cancer; Breast Neoplasm; Breast Cancer Metastatic; End Stage Cancer
- Interventions
- SV-BR-1-GM; Cyclophosphamide; Interferon infiltration of the inoculation site; Retifanlimab; Treatment of Physician's Choice
- Arms
- Bria-IMT Regimen + CPI · Experimental
- Treatment of Physician's Choice · Active comparator
- Bria-IMT Regimen Alone · Experimental
- Enrollment
- 404 (estimated)
- Primary outcomes
- Overall Survival
- Sponsor
- BriaCell Therapeutics Corporation
- Start
- Dec 5, 2023
- Primary completion
- Dec 2027 (estimated)
- Results posted
- No
- Registry record
- NCT06072612 · updated Sep 2, 2026